Company
Galapagos NV
Headquarters: Mechelen, Belgium
Founded: 1999
Employees: 1,309
CEO: Mr. Onno Van De Stolpe
Market Cap
€2.50 Billion
EUR as of Jan. 1, 2024
US$2.77 Billion
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $461.52 B |
| Vertex Pharmaceuticals Incorporated | $107.23 B |
| Regeneron Pharmaceuticals, Inc. | $100.01 B |
| CSL Limited | $94.74 B |
| Marinomed Biotech AG | $73.23 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Top 1-year algo backtest: +284.14%
$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
Galapagos NV has the following listings and related stock indices.
Stock: Euronext: GLPGA wb_incandescent
Stock: FSX: GXE wb_incandescent
Stock: NASDAQ: GLPG wb_incandescent
Stock: MTA: GXE wb_incandescent
Stock: XETR: GXE wb_incandescent
Stock: OTC: GLPGF wb_incandescent
Stock: FSX: GXEA wb_incandescent
Product & Services
filgotinib; GLPG1205; GLPG0778
Key People
Onno van de Stolpe (CEO), Raj Parekh (Chairman)
Financials
Revenue: €288.836 million (2018)
Net income: €-29.259 million (2018)
Total assets: €1,439.496 million (2018)
Total equity: €1,214.249 million (2018)